All of the Company's financial liabilities except lease liabilities are current liabilities with expected settlem dates within one year. The maturity analysis for lease liabilities is disclosed in note 14

cForeign exchange risk

The Company is exposed to foreign exchange risk due to its investments in foreign operations whose functional currency is the Euro.As of December 31,2022,if the US dollar had increased or decreased by 10% against the Euro, with all other variables held constant, net loss for the year ended December 31,2022 would have been lower 0r higher by approximately $8232021-$300 and 2020-$110.

# 25.

ent being the bionharmaceutical segment

Geographical information

|  |  |  |  |
| --- | --- | --- | --- |
|  | Years ended December 31, | | |
|  | 2022 | 2021 | 2020 |
|  | $ | $ | $ |
| Switzerland | 5,395 | 5,075 | 905 |
| Ireland | 82 |  | 73 |
| Denmark | 160 | 185 | 2,655 |
| Other | 3 |  | 19 |
|  | 5,640 | 5,260 | 3,652 |

Non-current assets include restricted cash equivalents, right of use assets, property and equipment, identifial ntangible assets, other asset and goodwill (2021 only) and are detailed by geographical area as follows

|  |
| --- |
| December 31, 2021 |
| 2022 $ |
|  |
| $ 463 9,212 |
| 4 |
| 71 70 538 9,282 |